TX-SUBJECTWELL
SubjectWell, the patient access marketplace that connects patients with chronic health conditions to new care options, today announced the acquisition of PatientCentra, an MD Connect, Inc. business. Located in Waltham, MA, PatientCentra offers full-service, global patient recruitment capabilities plus an in-house agency for the development of tailored, patient-centric recruitment journeys. Through this acquisition, SubjectWell now serves the patient recruitment needs of any international clinical study, while expanding its ability to recruit for rare disease and oncology indications.
“SubjectWell’s global customer base has been asking for our recruitment support on large, multi-country trials – and we listened,” said Fred Martin, CEO, SubjectWell. “PatientCentra has 15 years of experience delivering digitally enabled patient recruitment programs on five different continents. When added to SubjectWell’s unrivaled access to motivated patients with known conditions in North America, together we accelerate our ability to support life-improving research on a global scale.”
“The PatientCentra team and I are proud to be joining SubjectWell,” said Dan Stempel, founder and CEO, PatientCentra. “We see a huge opportunity to offer our customized clinical recruitment solutions, including multi-channel outreach, patient websites and concierge support to SubjectWell’s marquee customer base. Our combined customers can now rely on one company for end-to-end, global patient recruitment support for vaccine, chronic conditions, rare disease, and oncology studies.”
About SubjectWell
SubjectWell is the patient access marketplace, connecting patients with chronic health conditions to trials and treatments. Since 2012, SubjectWell has been raising awareness of the benefits of clinical research, registering tens of millions of healthcare-motivated patients with known conditions. At SubjectWell, we already have the patients you need. Visit www.SubjectWell.com to find out more.
About MD Connect, Inc.
For more than 15 years, MD Connect, Inc. has helped hundreds of leading healthcare organizations acquire patients using customized multi-channel digital outreach and patient lead tracking technologies. Backed by data and the experience of having driven millions of patient leads in over 30 specialties, MD Connect, Inc. leverages their knowledge base to map custom digital patient journeys that go well beyond an initial patient inquiry. PatientCentra, the largest and fastest growing component of MD Connect, Inc., provides global patient recruitment and compliance services, combining innovative outreach strategies with state-of-the-art technologies and a suite of site support services designed to ease the burden on patients, sites, and sponsors. Find out more at PatientCentra.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231102566400/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 202524.7.2025 23:02:00 CEST | Press release
- Mini oral presentation to highlight initial Phase 1 data of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, in patients with advanced or metastatic solid tumors - Oral presentation to feature initial data of INCB161734, a novel, selective and orally bioavailable inhibitor of G12D-mutated KRAS, in patients with advanced or metastatic solid tumors with KRASG12D mutations Incyte (Nasdaq:INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2025, to be held October 17-21 in Berlin. “We're looking forward to presenting the latest findings across our oncology portfolio at this year’s congress, including initial data for our TGFβR2×PD-1-directed bispecific antibody, INCA33890, and our novel, selective and orally bioavailable inhibitor of G12D-mutated KRAS, INCB161734,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data undersc
DNIB.com Reports Internet Has 371.7 Million Domain Name Registrations at the End of the Second Quarter of 202524.7.2025 23:01:00 CEST | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that, according to the latest Domain Name Industry Brief Quarterly Report from DNIB.com, the second quarter of 2025 closed with 371.7 million domain name registrations across all top-level domains (TLDs), an increase of 3.3 million domain name registrations, or 0.9% compared to the first quarter of 2025. Domain name registrations also increased by 9.3 million, or 2.6%, year over year. The .com and .net TLDs had a combined total of 170.5 million domain name registrations in the domain name base at the end of the second quarter of 2025, an increase of 0.7 million domain name registrations, or 0.4% compared to the first quarter of 2025. The .com and .net TLDs had a combined decrease of 0.1 million domain name registrations, or 0.1%, year over year. As of June 30, 2025, the .com domain name base totaled 157.9 million domain name registrations and the .net
SES and the Luxembourg Government to Develop and Launch New Defence Satellite for GovSat24.7.2025 18:55:00 CEST | Press release
GovSat-2 is aimed at meeting growing demand for highly secure, flexible MILSATCOM services SES and the Luxembourg Government today announced their plan for development of a second satellite for GovSat (LuxGovSat S.A.), the public-private partnership and 50/50 joint venture between SES and the Luxembourg Government that provides secure, reliable and accessible satellite communication services for governments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250724379713/en/ GovSat-2. Copyright: Thales Alenia Space GovSat-2 will be positioned over the European satellite arc. It will join GovSat-1 in augmenting reliable connectivity services for government customers over the region. The satellite will be built by Thales Alenia Space on its Spacebus 4000B2 platform. Since launching in 2018, the joint venture’s first defence satellite, GovSat-1, operated by GovSat from a secure missions operations centre in Luxembourg, has supporte
Infobip Named a Leader in 2025 Gartner® Magic Quadrant™ for Communications Platform-as-a-Service for the Third Consecutive Year24.7.2025 18:21:00 CEST | Press release
Infobip positioned furthest in Completeness of Vision Global communications platformInfobiphas once again been named a Leader in the 2025 Gartner Magic Quadrant for Communications Platform-as-a-Service (CPaaS)1. This year the company is placed furthest in Completeness of Vision. Infobip views this third consecutive recognition as acknowledging its status as a global CPaaS powerhouse. Magic Quadrant2 reports are a culmination of rigorous, fact-based research in specific markets, providing a wide-angle view of the relative positions of the providers in markets where growth is high and provider differentiation is distinct. Providers are positioned into four quadrants: Leaders, Challengers, Visionaries and Niche Players. The research enables customers to get the most from market analysis in alignment with their unique business and technology needs. As a Leader, Infobip is recognized for both its Ability to Execute and its Completeness of Vision. Infobip powers conversations for some of the
Andersen Consulting fremmer digitale transformationsmuligheder med eksponentielle digitale løsninger24.7.2025 17:43:00 CEST | Pressemeddelelse
Andersen Consulting fortsætter med at opbygge sin digitale konsulentplatform gennem et samarbejde med Exponential Digital Solutions (10xDS), et firma der specialiserer sig i AI-drevet transformation og nye teknologier. 10xDS blev stiftet i 2016 af adminstrerende direktør Binu Koshy og leverer next generation-løsninger inden for automatisering, analyse, kunstig intelligens, cybersikkerhed og udvikling af digitale produkter. Virksomhedens tværfaglige tilgang kombinerer teknisk ekspertise med strategisk indsigt og støtter kunderne i deres implementering og skalering af next generation-løsninger. Med international erfaring inden for forskellige brancher arbejder 10xDS på at løse operationelle ineffektiviteter og skabe ny værdi gennem digital innovation. "Hos 10xDS har vi opbygget en organisation, der er baseret på innovation og troen på, at AI og nye teknologier kan føre til betydeligt bedre forretningsresultater," siger Binu. "Dette samarbejde understøtter vores mission om at skalere tran
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom